uploads///Graph Part  OCt

IMMU and ACRX Outperform in the Biotech Downdraft

By

Nov. 20 2020, Updated 3:52 p.m. ET

IBB’s bottom ten small-cap stocks outperform

In the small-cap space, the bottom ten stocks of the iShares Nasdaq Biotechnology ETF (IBB) outperformed the bottom ten stocks of the SPDR S&P Biotechnology ETF (XBI) with a return of -0.14% and -3%, respectively, on October 6, 2015.

The above graph shows the performance of IBB and XBI’s bottom ten stocks on October 6, 2015. On a trailing five-day basis, IBB outperformed XBI with a return of 9.1% compared to XBI’s return of 3.7%.

Article continues below advertisement

Immunomedics and Acelrx Pharmaceuticals outperform

Immunomedics (IMMU) rose by 13% on October 6, 2015. The stock rose on buying support with good trade volumes. On October 6, 2015, ~1.1 million shares were traded. The stock closed at $2.08. It was trading above the 20-day and 50-day moving averages. However, it was below the 100-day moving averages.

Acelrx (ACRX) rose by 4.2% on October 6, 2015. The stock rose due to the news of the initiation of the ARX-04 Phase 3 study. According to the press release, “ACRX announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. The primary efficacy endpoint is the summed pain intensity difference (SPID) over 1-hour (SPID1). Safety endpoints, such as adverse events and vital signs will also be assessed, as will the patients’ and healthcare providers’ satisfaction with the method of pain control. The study is expected to be completed in early 2016.” Acelrx closed at $3.48. It was trading below the 20-day, 50-day, and 100-day moving averages.

Investors can also invest indirectly in these stocks through IBB. It holds stocks like Acadia Pharmaceuticals (ACAD), Dyax (DYAX) and Kite Pharmaceuticals (KITE). They had returns of -6.1%, 3.4%, and 1.6% on October 6, 2015.

Advertisement

More From Market Realist

  • BioNano Genomics Saphyr system
    Company & Industry Overviews
    BioNano Genomics (BNGO) Stock Looks Like a Buy, Solid Opportunity
  • Delta aircraft
    Company & Industry Overviews
    Delta Air Lines Updates Mandatory Vaccine Policy, Explained
  • AMC advertisement in walkway
    Company & Industry Overviews
    Why It's Time for Most Investors to Sell AMC Entertainment Stock
  • 100 Thieves founder Matthew Haag
    Company & Industry Overviews
    Why Growing Esports Company 100 Thieves Isn't Publicly Traded
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.